Clinical trial · Interventional
Needle Localization During Prostate Brachytherapy Using Power Doppler Ultrasound
NCT03861507CI-TRIAL-00087813recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study involves patients who are scheduled for standard care brachytherapy of focal tumours within the prostate, which is normally performed under standard 2-dimensional (2D) ultrasound guidance. The purpose of this study is the acquire power Doppler ultrasound while using a simple oscillator in physical contact with the end of a brachytherapy needle. The vibrations along the needle should be visible in the power Doppler ultrasound, helping to visualize the needle position within the anatomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prostate Brachytherapy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patient
- description
- Patient undergoing standard care prostate high dose rate brachytherapy.
- interventionNames
- Device: Prostate Brachytherapy
Primary outcomes (1)
- measure
- Needle Trajectory
- timeFrame
- 1 month following data collection
- description
- Intra-operative needle trajectories in B-mode and power Doppler ultrasound
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male, aged 18 years or older * Willing to provide written consent * Pathologically confirmed prostate cancer on previous biopsy * Suitable for and consenting to high-dose-rate brachytherapy for treatment as standard of care. Exclusion Criteria: * • Previous radiotherapy to the prostate
References
Publications (0)
Data not yet available
No reference posted for this study.